Suraksha Diagnostic FY26 Performance and Dividend Update

Revenue from operations reached Rs 310.41 crore in FY26 compared to Rs 252.09 crore in FY25. Profit for the year stood at Rs 31.40 crore against Rs 30.98 crore in the previous fiscal.

Reader Takeaway: Revenue growth and strategic acquisitions in genomics and foetal medicine drive expansion, offset by localized auditor observations.

What just happened

Suraksha Diagnostic has announced its 21st Annual General Meeting (AGM) for September 22, 2026, via video conferencing. The Board has recommended a final dividend of Rs 0.50 per equity share for the financial year ending March 31, 2026. The record date for this dividend is set for September 15, 2026.

Why this matters

The dividend announcement signals consistent cash flow generation for shareholders. Furthermore, the company has scaled its footprint, now operating 68 diagnostic centres and 193 collection centres. The successful integration of genomics testing and the 63% acquisition of Fetomat Wellness are key pillars for the company's entry into high-margin specialized diagnostics.

Business and Strategic Updates

The firm has actively invested in advanced technology, notably the Genexus NGS platform for genetic testing. Its operational performance saw the company serve 0.14 crore patients and process 0.82 crore tests throughout the last fiscal year.

Risks to watch

Statutory auditors noted that while the mandatory audit trail software was implemented in October 2025, they could not verify audit trail records for the prior period as the functionality was not enabled before that date. Investors should monitor how the company integrates these new business verticals into its existing revenue stream to sustain margin profiles.

Context metrics

Total income rose to Rs 313.58 crore in FY26 from Rs 255.94 crore in FY25. EBITDA for the same period was reported at Rs 98.56 crore, up from Rs 85.09 crore.